Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
filingDate |
2000-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_038818efe6295ac50df7b6b735b87843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86e67d70efe1695c3a2a040d112e72a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94cb222a1b4d2d420469dcc6f1d74288 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a922e91f699c9e170b24526d698c5c8 |
publicationDate |
2000-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2372236-A1 |
titleOfInvention |
Polymorphs of crystalline (2-benzhydryl-1-azabicyclo¬2,2,2|oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists |
abstract |
Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are Form A and Form B. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in patient receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule and intravenous. A method of making A and B Forms is also disclosed. |
priorityDate |
1999-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |